HighTide Therapeutics Inc (2511.HK)
HKD 1.11
(14.43%)
HKD 1.11
(14.43%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.03 Billion CNY | -369.18% |
| 2022 | -221.22 Million CNY | 17.0% |
| 2021 | -266.52 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -113.33 Thousand HKD | 0.15% |
| 2024 Q1 | -114.3 Thousand HKD | 99.97% |
| 2023 Q1 | -314.19 Thousand HKD | 99.76% |
| 2023 Q4 | -420.85 Million HKD | -201351.28% |
| 2023 Q3 | -208.91 Thousand HKD | 99.97% |
| 2023 Q2 | -621.73 Million HKD | -197784.82% |
| 2023 FY | -1.03 Billion CNY | -369.18% |
| 2022 Q2 | -89.57 Million HKD | 0.0% |
| 2022 FY | -221.22 Million CNY | 17.0% |
| 2022 Q4 | -130.22 Million HKD | 0.0% |
| 2021 FY | -266.52 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 70.87 Million HKD | 1564.433% |
| CK Life Sciences Int'l., (Holdings) Inc. | 17.25 Million HKD | 6116.993% |